secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001808805-24-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY
--------------------------------------------------------------------------------

- Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.
- Operating expenses of $20.8M, up $1.8M or 9% from $19.0M a year ago.
- Cash, equivalents, and investments of $232.9M as of June 30, 2024.
- Expense increase driven by higher headcount to support product development.
- Company continues development of single-molecule proteome analysis platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000055/0001808805-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000055/naut-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001808805-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer